These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 1587072)

  • 1. Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo.
    Weintraub M; Sundaresan PR; Madan M; Schuster B; Balder A; Lasagna L; Cox C
    Clin Pharmacol Ther; 1992 May; 51(5):586-94. PubMed ID: 1587072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term weight control study. II (weeks 34 to 104). An open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise.
    Weintraub M; Sundaresan PR; Schuster B; Ginsberg G; Madan M; Balder A; Stein EC; Byrne L
    Clin Pharmacol Ther; 1992 May; 51(5):595-601. PubMed ID: 1587073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term weight control study. IV (weeks 156 to 190). The second double-blind phase.
    Weintraub M; Sundaresan PR; Schuster B; Averbuch M; Stein EC; Cox C; Byrne L
    Clin Pharmacol Ther; 1992 May; 51(5):608-14. PubMed ID: 1587075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term weight control study. V (weeks 190 to 210). Follow-up of participants after cessation of medication.
    Weintraub M; Sundaresan PR; Schuster B; Averbuch M; Stein EC; Byrne L
    Clin Pharmacol Ther; 1992 May; 51(5):615-8. PubMed ID: 1587076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic induction of weight loss to treat type 2 diabetes.
    Redmon JB; Raatz SK; Kwong CA; Swanson JE; Thomas W; Bantle JP
    Diabetes Care; 1999 Jun; 22(6):896-903. PubMed ID: 10372238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term weight control study. III (weeks 104 to 156). An open-label study of dose adjustment of fenfluramine and phentermine.
    Weintraub M; Sundaresan PR; Schuster B; Moscucci M; Stein EC
    Clin Pharmacol Ther; 1992 May; 51(5):602-7. PubMed ID: 1587074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination.
    Weintraub M; Hasday JD; Mushlin AI; Lockwood DH
    Arch Intern Med; 1984 Jun; 144(6):1143-8. PubMed ID: 6375610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine.
    Hensrud DD; Connolly HM; Grogan M; Miller FA; Bailey KR; Jensen MD
    Mayo Clin Proc; 1999 Dec; 74(12):1191-7. PubMed ID: 10593346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term weight control study. VI. Individual participant response patterns.
    Weintraub M; Sundaresan PR; Cox C
    Clin Pharmacol Ther; 1992 May; 51(5):619-33. PubMed ID: 1587077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lower dosages of phentermine-fenfluramine given in the afternoon: five cases with significant weight loss.
    Katz DA; Maloney MJ; Sutkamp JC; McConville BJ
    Int J Eat Disord; 1999 May; 25(4):469-74. PubMed ID: 10202659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term weight control study: conclusions.
    Weintraub M
    Clin Pharmacol Ther; 1992 May; 51(5):642-6. PubMed ID: 1587079
    [No Abstract]   [Full Text] [Related]  

  • 12. Long-term weight control study. VII (weeks 0 to 210). Serum lipid changes.
    Weintraub M; Sundaresan PR; Schuster B
    Clin Pharmacol Ther; 1992 May; 51(5):634-41. PubMed ID: 1587078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenylpropanolamine OROS (Acutrim) vs. placebo in combination with caloric restriction and physician-managed behavior modification.
    Weintraub M; Ginsberg G; Stein EC; Sundaresan PR; Schuster B; O'Connor P; Byrne LM
    Clin Pharmacol Ther; 1986 May; 39(5):501-9. PubMed ID: 3516509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term drug treatment of obesity in a private practice setting.
    Atkinson RL; Blank RC; Schumacher D; Dhurandhar NV; Ritch DL
    Obes Res; 1997 Nov; 5(6):578-86. PubMed ID: 9449143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of liraglutide plus phentermine in adults with obesity following 1 year of treatment by liraglutide alone: A randomized placebo-controlled pilot trial.
    Tronieri JS; Wadden TA; Walsh OA; Berkowitz RI; Alamuddin N; Gruber K; Leonard S; Chao AM
    Metabolism; 2019 Jul; 96():83-91. PubMed ID: 30902750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.
    Gadde KM; Allison DB; Ryan DH; Peterson CA; Troupin B; Schwiers ML; Day WW
    Lancet; 2011 Apr; 377(9774):1341-52. PubMed ID: 21481449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lifestyle modification in the pharmacologic treatment of obesity: a pilot investigation of a potential primary care approach.
    Wadden TA; Berkowitz RI; Vogt RA; Steen SN; Stunkard AJ; Foster GD
    Obes Res; 1997 May; 5(3):218-26. PubMed ID: 9192396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful appetite suppression therapy with fenfluramine and phentermine in the obese diabetic transplant patient.
    Khan M; Lum CT; Rao V
    Transplant Proc; 1995 Feb; 27(1):975-6. PubMed ID: 7879251
    [No Abstract]   [Full Text] [Related]  

  • 19. Body weight loss with phentermine alone versus phentermine and fenfluramine with very-low-calorie diet in an outpatient obesity management program: a retrospective study.
    Li Z; Hong K; Yip I; Huerta S; Bowerman S; Walker J; Wang H; Elashoff R; Go VL; Heber D
    Curr Ther Res Clin Exp; 2003 Jul; 64(7):447-60. PubMed ID: 24944395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of a combined behavioral and pharmacological program on weight loss.
    Brightwell DR; Naylor CS
    Int J Obes; 1979; 3(2):141-8. PubMed ID: 528125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.